A196 AN EXTRA BENEFIT TO USING STATINS: A CLINICAL OBSERVATIONAL STUDY ON NAFLD PATIENTS (PILOT STUDY)
Bibliographic record
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide – with an estimated 25% of Canadians affected. NAFLD has the potential to progress to nonalcoholic steatohepatitis (NASH), cirrhosis and fibrosis of the liver, and ultimately, liver failure. Globally, cirrhosis affects 1.6% people. NAFLD is often asymptomatic and found in people with metabolic syndrome. Both conditions can progress to an adverse event which relies on antidyslipidemic agents for treatment. The first-line of treatment for patients with dyslipidemia are statins. Recently, the use of statins has been suggested to be safe in NAFLD patients, but there is a lack in certainty of its effectivity in treating liver disease. To determine if statins are effective for NAFLD treatment. An observational study was conducted at the NorthGate Clinic, by searching for patients undergoing statin treatment with NAFLD suppression. A FibroScore was obtained for the patients to establish the severity of liver damage and NAFLD. Patients were then retested to obtain a post-stain use FibroScore. Alanine transaminase (ALT) and aspartate transaminase (AST) levels, another measure of liver condition, were also assessed with the continued usage of statins. After determining the cases with NAFLD, these cases were then included based on their improvement post-statin usage. A total of 27 patients from the NorthGate Clinic met the inclusion criteria. These NAFLD patients were on statins to treat some form of dyslipidemia, and found an additional benefit of the drug – suppression of the symptoms of and treatment of NAFLD. However, only 21 patients had pre- and post-FibroScore data. Overall, patients found a decrease in FibroScore, ALT and AST levels with the continued usage of statins. Evidence from the observational study indicated that the use of statins was associated with the suppression of NAFLD symptoms and a lower FibroScore, and ALT and AST levels. In general, this study suggests that the usage of statins was beneficial and safe in a particular sub-segment of the Canadian population with NAFLD. Therefore, suggesting that NAFLD patients are a population of interest. Limitations of the observational study included insufficient statistical power, uncontrolled selection bias and confounding factors. Moreover, since the data was obtained retrospectively, some data was missing. Thus, this study cannot assert that usage of statins induced an improvement to the liver (lower AST and ALT levels, and FibroScore). Currently, available studies indicate that the benefits of statins outweigh the adverse effects of these drugs in NAFLD patients. Additional research needs to be provided on the long-term side effects associated with the use of statins in this population. Future studies should focus on providing more evidence to support the effect of statins in NAFLD patients. None
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".